دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion
TrevorSimardMDa?Richard G.JungBScb?KyleLehenbauerMDcKerstinPiaydaMDdeRadoslawPraco?MD, PhDfGregory G.JacksonMDgEduardoFlores-UmanzorMDhLaurentFarouxMDiKasperKorsholmMD, PhDjJulian K.R.ChunMDkShaojieChenMDkMoniekMaarseMDlmKristiMontrellaCRNPnZakeihChakerMDoJocelyn N.SpoonMDpLuigi E.PastormerloMDqFelixMeinckeMDrAbhishek C.SawantMDs…MohamadAlkhouliMDa
doi : 10.1016/j.jacc.2021.04.098
Volume 78, Issue 4, 27 July 2021, Pages 297-313
Device-related thrombus (DRT) has been considered an Achilles’ heel of left atrial appendage occlusion (LAAO). However, data on DRT prediction remain limited.
Device-Related Thrombus After Left Atrial Appendage Occlusion?
OussamaWazniMDWalidSalibaMDAyman A.HusseinMD
doi : 10.1016/j.jacc.2021.05.028
Volume 78, Issue 4, 27 July 2021, Pages 314-316
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial
Rupert M.BauersachsMDabMichaelSzarekPhDcdeMarianneBrodmannMDfIvanGudzMDgEike SebastianDebusMD, PhDhMark R.NehlerMDiSonia S.AnandMDjManesh R.PatelMDkConnie N.HessMD, MHSdWarren H.CapellMDlKevinRogersMDdEvaMuehlhoferMDmLloyd P.HaskellMD, MBAnScott D.BerkowitzMDoWilliam R.HiattMDcdMarc P.BonacaMD, MPHcdVOYAGER PAD Committees and Investigators
doi : 10.1016/j.jacc.2021.05.003
Volume 78, Issue 4, 27 July 2021, Pages 317-326
Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb and cardiovascular events. The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) trial demonstrated that rivaroxaban 2.5 mg twice daily reduced first events by 15%. The benefit of rivaroxaban on total (first and subsequent) events in this population is unknown.
Wider Lens, Sharper Focus?
Gregory L.MonetaMD
doi : 10.1016/j.jacc.2021.05.023
Volume 78, Issue 4, 27 July 2021, Pages 327-329
Kidney Function and Outcomes in Patients Hospitalized With Heart Failure
Ravi B.PatelMD, MScaGregg C.FonarowMDbStephen J.GreeneMDcdShuaiqiZhangMSdBrookeAlhantiPhDdAdam D.DeVoreMD, MHScdJavedButlerMD, MPH, MBAePaul A.HeidenreichMDfJoanna C.HuangPharmDgMichelle M.KittlesonMD, PhDhKaren E.Joynt MaddoxMD, MPHiJames J.McDermottPhDgAnjali TikuOwensMDjPamela N.PetersonMD, MSPHklScott D.SolomonMDmOrlyVardenyPharmD, MSnClyde W.YancyMD MScaMuthiahVaduganathanMD, MPHm
doi : 10.1016/j.jacc.2021.05.002
Volume 78, Issue 4, 27 July 2021, Pages 330-343
Few contemporary data exist evaluating care patterns and outcomes in heart failure (HF) across the spectrum of kidney function.
Heart Failure and Chronic Kidney Disease Patients: First It Is Necessary to Act?
PatrickRossignolMD, PhDaBertramPittMDb
doi : 10.1016/j.jacc.2021.05.027
Volume 78, Issue 4, 27 July 2021, Pages 344-347
Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial
Charles A.HerzogMDabMengistu A.SimegnMDabYifanXuMPHcSalvatore P.CostaMDdRoy O.MathewMDeMohammad C.El-HajjarMDfSanjeevGulatiMDgRafael A.MaldonadoMDhEricDaugasMD, PhDiMagdelenaMaderoMDjJerome L.FlegMDkRebeccaAnthopolosDrPHcGregg W.StoneMDlMandeep S.SidhuMDfDavid J.MaronMDmJudith S.HochmanMDcSripalBangaloreMD, MHAc
doi : 10.1016/j.jacc.2021.05.001
Volume 78, Issue 4, 27 July 2021, Pages 348-361
Patients with chronic kidney disease (CKD) and coronary artery disease frequently undergo preemptive revascularization before kidney transplant listing.
Treating Myocardial Ischemia Before Kidney Transplantation: Time for a Reappraisal?
UsmanBaberMD, MS
doi : 10.1016/j.jacc.2021.05.033
Volume 78, Issue 4, 27 July 2021, Pages 362-364
Myocardial Revascularization Surgery: JACC Historical Breakthroughs in Perspective
Michael J.MackMDaJohn J.SquiersMDaBruce W.LytleMDaJ. MichaelDiMaioMDaFriedrich W.MohrMDb
doi : 10.1016/j.jacc.2021.04.099
Volume 78, Issue 4, 27 July 2021, Pages 365-383
Coronary artery bypass grafting (CABG) was introduced in the 1960s as the first procedure for direct coronary artery revascularization and rapidly became one of the most common surgical procedures worldwide, with an overall total of more than 20 million operations performed.
Percutaneous Coronary Revascularization: JACC Historical Breakthroughs in Perspective
Patrick W.SerruysMD, PhDabc?MasafumiOnoMDabd?ScotGargMD, PhDeHironoriHaraMDabdHideyukiKawashimaMDabdGiulioPompilioMD, PhDfgDanieleAndreiniMD, PhDfhDavid R.HolmesJr.MDiYoshinobuOnumaMD, PhDabSpencer B.King IIIMDj
doi : 10.1016/j.jacc.2021.05.024
Volume 78, Issue 4, 27 July 2021, Pages 384-407
Over the last 4 decades, percutaneous coronary intervention has evolved dramatically and is now an acceptable treatment option for patients with advanced coronary artery disease. However, trialists have struggled to establish the respective roles for percutaneous coronary intervention and coronary artery bypass graft surgery, especially in patients with multivessel disease and unprotected left-main stem coronary artery disease. Several pivotal trials and meta-analyses comparing these 2 revascularization strategies have enabled the relative merits of each technique to be established with regard to the type of ischemic syndrome, the coronary anatomy, and the patient’s overall comorbidity.
Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19
BehnoodBikdeliMD, MSabcSauravChatterjeeMDdShilpkumarAroraMD, MPHeManuelMonrealMD, PhDfDavidJimenezMD, PhDgHarlan M.KrumholzMD, SMbhiSamuel Z.GoldhaberMDaMitchell S.V.ElkindMD, MSjGregoryPiazzaMD, Msa
doi : 10.1016/j.jacc.2021.06.001
Volume 78, Issue 4, 27 July 2021, Pages 408-411
Navigating the Path to Digital Transformation
DiptiItchhaporiaMD, FACC(President, American College of Cardiology)
doi : 10.1016/j.jacc.2021.06.018
Volume 78, Issue 4, 27 July 2021, Pages 412-414
Causes of Death After Type 2 Myocardial Infarction and Myocardial Injury
Claire E.RaphaelMBBS, PhDVéronique L.RogerMD, MPHYaderSandovalMDMatthewJohnsonMSAllanJaffeMDAmirLermanMDCharanjit S.RihalMD, MBAMalcolm R.BellMDMandeepSinghMDRajivGulatiMD, PhD
doi : 10.1016/j.jacc.2021.05.026
Volume 78, Issue 4, 27 July 2021, Pages 415-416
Imaging Edema in Immune Checkpoint Inhibitor Myocarditis: A Moving Target
LucaArcariMDGiovanniCamastraMDFedericaCiolinaMD, PhDMassimilianoDantiMD, PhDLucaCacciottiMD, PhD
doi : 10.1016/j.jacc.2021.04.095
Volume 78, Issue 4, 27 July 2021, Pages 416-417
Reply: Imaging Edema in Immune Checkpoint Inhibitor Myocarditis: A Moving Target
PaaladineshThavendiranathanMD, SMLiliZhangMD, ScMTomas G.NeilanMD, MPH
doi : 10.1016/j.jacc.2021.05.019
Volume 78, Issue 4, 27 July 2021, Pages 417-418
Job Strain and Recurrent Coronary Events
JunliLiPhDYanguoXinPhD
doi : 10.1016/j.jacc.2021.04.097
Volume 78, Issue 4, 27 July 2021, Pages 418-419
Reply: Job Strain and Recurrent Coronary Events
XavierTrudelPhDChantalBrissonPhDDenisTalbotPhDMahéeGilbert-OuimetPhDAlainMilotMD
doi : 10.1016/j.jacc.2021.05.025
Volume 78, Issue 4, 27 July 2021, Page 419
